China eyes total dominance of pharma and biotech supply chains
New report warns Beijing’s growing influence across virtually every stage of the biotech supply chain could create vulnerabilities for the US.
Article label: Quick Read
China’s efforts to control the entire pharmaceutical supply chain, from drug manufacturing to novel treatment discovery, are the subject of a new report from the National Security Commission on Emerging Biotechnology (NSCEB).
The bipartisan, congressionally mandated commission studies how advances in biotechnology affect US national security, economic competitiveness, and strategic
